Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade

Victoria Klepsch, Natascha Hermann-Kleiter, Patricia Do-Dinh, Bojana Jakic, Anne Offermann, Mirjana Efremova, Sieghart Sopper, Dietmar Rieder, Anne Krogsdam, Gabriele Gamerith, Sven Perner, Alexandar Tzankov, Zlatko Trajanoski, Dominik Wolf and Gottfried Baier ()
Additional contact information
Victoria Klepsch: Medical University of Innsbruck
Natascha Hermann-Kleiter: Medical University of Innsbruck
Patricia Do-Dinh: Medical University of Innsbruck
Bojana Jakic: Medical University of Innsbruck
Anne Offermann: Campus Luebeck and Research Center Borstel
Mirjana Efremova: Medical University of Innsbruck
Sieghart Sopper: Tyrolean Cancer Institute & Internal Medicine V
Dietmar Rieder: Medical University of Innsbruck
Anne Krogsdam: Medical University of Innsbruck
Gabriele Gamerith: Tyrolean Cancer Institute & Internal Medicine V
Sven Perner: Campus Luebeck and Research Center Borstel
Alexandar Tzankov: University Hospital Basel
Zlatko Trajanoski: Tyrolean Cancer Institute & Internal Medicine V
Dominik Wolf: Tyrolean Cancer Institute & Internal Medicine V
Gottfried Baier: Medical University of Innsbruck

Nature Communications, 2018, vol. 9, issue 1, 1-13

Abstract: Abstract Analyzing mouse tumor models in vivo, human T cells ex vivo, and human lung cancer samples, we provide direct evidence that NR2F6 acts as an immune checkpoint. Genetic ablation of Nr2f6, particularly in combination with established cancer immune checkpoint blockade, efficiently delays tumor progression and improves survival in experimental mouse models. The target genes deregulated in intratumoral T lymphocytes upon genetic ablation of Nr2f6 alone or together with PD-L1 blockade reveal multiple advantageous transcriptional alterations. Acute Nr2f6 silencing in both mouse and human T cells induces hyper-responsiveness that establishes a non-redundant T-cell-inhibitory function of NR2F6. NR2F6 protein expression in T-cell-infiltrating human NSCLC is upregulated in 54% of the cases (n = 303) and significantly correlates with PD-1 and CTLA-4 expression. Our data define NR2F6 as an intracellular immune checkpoint that suppresses adaptive anti-cancer immune responses and set the stage for clinical validation of targeting NR2F6 for next-generation immuno-oncological regimens.

Date: 2018
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-018-04004-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-04004-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-04004-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().